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The Saga of Liver Replacement, with Particular 
Reference to the Reciprocal Influel1ce of Liver and 
Kidney Transplantation (1955-1967) 
Thomas E Srarzi, MO, PhD, FACS 
Between 1955 and the end of 1967, the framework of 
clinical organ transplantation that exists today was es-
tablished in a small number of centers in continental 
Europe, Great Britain, and the North America. Here, I 
will describe the events during this period that led to 
human liver replacement. These efforrs were influenced 
by, and in turn contributed to, the development of other 
kinds of organ transplantation, and especially that of the 
kidney. 
The geneSis of liver transplantation 
As described by the immunologist, Leslie Brent, I and the 
Glasgow surgeon-historian David Hamilton / trans-
plantation of all the major organs except the liver can be 
traced back to the early 1900s. In contrast, liver trans-
Figure 1. C Stuart Welch (1909-1980), the author of the first 
article in the literature on liver transplantation, Information about 
Welch's tragic personal life can be found in: Starzl TE: The Puzzle 
People: Memoirs of a Transplant Surgeon. PittSburgh, PA: University 
of Pittsburgh Press; 1992. 
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plantation was not mentioned in the literature until 
1955. The first report was in a journal called Transplan-
tation Bulletin, the forerunner of the current 
Transplantation. 
Figure 2. Auxiliary liver homotransplantation in dogs (the Welch 
procedure). Note that the reconstituted portal venous inflow is from 
the inferior vena caval bed rather than from the splanchnic organs. 
Biliary drainage was with cholecystoduodenostomy. a, artery; v, 
vein. (From: Starzl TE, Marchioro TL. Rowlands DT Jr, et al. Immu· 
nosuppression after experimental and clinical homotransplantation 
of the liver. Ann Surg 1964;160:411-439; with permission .) 
ISSN 1072·7515/ 02/$21.00 
PII S1072·7515(02)01498·9 
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Figure 3. Hepatic fossa after removal of the liver with preservation 
of the retrohepatic inferior vena cava. Duod., duodenum; P.v., portal 
vein; V.c., vena cava. (From: Starzl TE, Bernhard VM, Benvenuto R, 
Cortes N. A new method for one-stage hepatectomy in dogs. Surgery 
1959; 46:880-886; with permission) 
The auxiliary liver concept 
In this one-page article, C Stuart Welch of Albany Med-
ical College (Fig. 1), described the inserrion of a hepatic 
allograft in the right paravertebral gutter of dogs, with-
out disrurbing the native liver.3 A more complete report 
was published in Surgery the following year. 4 The auxil-
iary livers were revascularized by anastomosing the graft 
Post. rO\v 
J Am Coli Surg 
Figure 4, Canine liver allograft. The graft includes the segment of 
retrohepatic inferior vena cava into which the hepatic veins empty. 
G,b., gallbladder; H.a" hepatic artery; P.v .. portal vein . (From: Starzl 
T, Kaupp H Jr, Brock D, et al. Reconstructive problems in canine liver 
homotransplantation with special reference to the postoperative 
role of hepatic venous flow. Surg Gynecol Obstet 1960;111:733-
743, with permission.) 
~ .. " ; .. 
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Figure 5, Intraluminal everting suture technique for close-quarter vena caval anastomoses. Ant., anterior; Post.. posterior. (From: Starzl T, 
Kaupp H Jr, Brock D, et al. Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of 
hepatic venous ftow. Surg Gynecol Obstet 1960;111:733-743, with permission,) 
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Figure 6. Alternative methods of portal vein revascularization. (A) reverse Eck fistula. (B) with small side-to-side portacaval shunt. (C) 
anatomically normal. Survival was best with C. P.v., portal vein. (From: Starzl T, Kaupp H Jr, Brock 0, et al. Reconstructive problems in canine 
liver homotransplantation with spec ial reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet 1960;111:733-743, 
with permission.) 
hepatic anery w the recipiem aorwiliac system, and by 
end-w-end anas[Omosis of me ponal vein w the host 
inferior vena cava (Fig. 2). The transplamed organs un-
derwem dramatic shrinkage, a finding that was incor-
Figure 7. Jack A Cannon (1919-). the first surgeon to attempt 
experimental liver replacement. The work was done in 1956 at the 
then new medical school of the University of California Los Angeles 
(UCLA). 
recdy considered for most of the next decade [0 be a 
special feature of liver rejection. 
In 1957, Welch gave a lecture on his experimenral oper-
ation during a visiting professorship at me University of 
Miami Medical School, where I was a general slligery resi-
den [. Because he had provided me auxiliary grafts wim high 
flow input of systemic venous blood from me recipient 
Figure 8. Francis 0 Moore (1913-2001), professor of surgery at 
Harvard Medical College, and chief of surgery at the Peter Bent 
Brigham Hospital, Boston, Moore instituted a program of canine 
liver replacement in the summer of 1958, and attempted one of the 
human procedures done in 1963. 
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Figure 9. Left: Norman Shumway (1923--) and the late F John Lewis 
(1916-1993) at an American College of Surgeons congress in the 
1970s. 
Figure 1.0. Cooling of canine hepatic allograft by infusion of chilled 
lactated Ringer's solution into the donor portal vein. The animals 
were simultaneously exsanguinated. G.b . gallbladder; H.a .. hepatic 
artery; P.v .• portal vein. (From: Starzl T. Kaupp H Jr. Brock D. et al. 
Reconstructive problems in canine liver homotransplantation with 
special reference to the postoperative role of hepatic venous flow. 
Surg Gynecol Obstet 1960;111:733-743. with permission .) 
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Figure 1.1.. Rewarming curve at room temperature of a canine liver 
that had been cooled by an infusion of chilled lactated Ringer's 
solution . The temperature probe was placed at the center of the 
allograft. (From: Starzl T. Kaupp H Jr. Brock D. et al. Reconstructive 
problems in canine liver homotransplantation with special reference 
to the postoperative role of hepatic venous flow. Surg Gynecol 
Obstet 1960;111:733-743, with permission.) 
inferior vena cava, Welch was convinced that his trans-
planted livers were optimally revascularized. 
Contrary to this assumption, I had been exploring the 
possibility that the first pass delivery of endogenous in-
sulin from the pancreas to the liver by portal blood was 
important in metabolic crossregulation of the two or-
gans. Evidence consistem with this hypothesis had come 
from studies of Eck's fistula (portacaval shunt) and re-
verse Eck's fistula. s.G If the hypothesis was correct, the 
Welch procedure was physiologically flawed. 
Liver replacement 
To pursue the metabolic studies, I had developed a new 
method of total hepatectomy.7 The unique feature of the 
procedure was preservation of the reuohepatic inferior 
vena cava, as is done in today's piggy-back modification 
of liver transplamations.,o (Fig. 3). Reimplantation (au-
touansplantation) of the excised specimen was soon en-
visioned as an ideal way to study the portal physiology of 
an unequivocally denervated liver that was devoid of 
cryptic collateral arteries. Welch had obviated the need 
to anastomose multiple hepatic veins by including as 
part of his auxiliary allografts the short length of vena 
cava into which all of these hepatic veins empty and by 
connecting the upper end of the caval stump to the 
recipient vena cava (Fig. 2). 
Vol. 195, NO.5, November 2002 
Rgure 12. Decompression of the portal and vena caval beds. This 
was done in Chicago with a single femoral vein to external jugular 
bypass after preliminary portacaval anastomosis." In Boston, se!}-
arate external shunts were used for individual decompression of the 
2 venous systems15 as shown in Figure 32. Ext., external; P.v., 
portal vein; S.V.C., superior vena cava. (From: Starzl T, Kaupp H Jr, 
Brock D, et al. Reconstructive problems in canine liver homotrans-
plantation with special reference to the postoperative role of hepatic 
venous flow. Surg Gynecol Obstet 1960;111:733-743, with 
permission .) 
For liver replacement, it was easiest to excise the host 
retrohepatic vena cava along with the native liver, and to 
replace it with the comparable caval segment of an allo-
graft (Fig. 4). Restoration of caval continuity required 
end-to-end anastomoses: one at the diaphragm and the 
other below the liver. The performance of everting anas-
tomoses in a confined space without the need for long 
vascular cuffs was made feasible by perfection of the 
intraluminal continuous suture technique used today 
(Fig. 5). Hepatic arterial and biliary tract anaStomoses 
were done with conventional methods. I] 
At first, none of the animals survived the operation. 
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Rgure 13. Survival in dogs who lived more than 4 days after liver 
replacement. Note: high mortality between 5th and 10th day. (From: 
Starzl TE, Kaupp HA Jr. Brock DR. Linman JW. Studies on the 
rejection of the transplanted homologous dog liver. (From Surg 
Gynecol Obstet 1961;112:135-144.) 
This finally was accomplished in June, 1958, a few days 
after I moved from Miami to Northwestern University 
in Chicago. During the rest of the summer, the different 
kinds of liver revascularization studied in Miami in non-
transplant models were systematically tested in allografts 
(Fig. 6). Any alteration of the portal supply resulted in 
reduced survival. Although the findings were congruent 
with the original hypothesis that splanchnic venous 
blood contains liver-modulating factors, this issue was 
not fully resolved for another 15 years. 
Two administrative steps were taken at the end of that 
summer that ensured crucial research support for at least 
5 years. The first was submission of a four-page NIH 
grant request for continued investigation of the liver's 
role in insulin and carbohydrate metabolism that in-
cluded liver transplantation. In addition, my North-
western chairman, Loyal Davis, nominated me for a 
Markle Scholarship; the purpose of these awards was to 
keep young faculty members in academic medicine in 
pursuit of some stipulated career objective. My proposal 
was the development of clinical liver transplantation. 
JUSt before Christmas, 1958, I was notified that the 
grant would be fully funded, and that I was to be a 
Markle scholar. 
Other early investigations 
Unknown to me in 1958, our attempts at liver replace-
ments had been preceded by those of a UCLA surgeon 
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Figure 14. (A) Donald Brock (1926-). As chief of pathology at the 
Northwestern VA (Research) Hospital in 1958-1960, Brock did the 
histopathologic analyses for the Chicago liver transplant studies in 
unmodified dogs. (B) Gustav Dammin (1911-1991) already was an 
acknowledged expert in kidney transplant pathology when he was 
recruited by Francis D Moore for the Brigham canine liver transplant 
initiative. 
named Jack Cannon (Fig. 7). Cannon, now 83 years old, 
later practiced in Phoenix where he has retired. In col-
laboration with William P LongmireJr, Cannon already 
had made important basic observations about spontane-
ous tolerance in a neonatal chick model of skin trans-
plantation, and the facilitation of such tolerance with 
adrenal corticosteroids. 12 The significance of this ne-
glected work is discussed elsewhere. 13 His liver trans-
plant experiments were mentioned in a one-page 
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Figure 15. Serial blood sugars and serum bilirubins in a nonimmu-
nosuppressed canine liver recipient who survived for 3 weeks. Note 
the decline of bilirubin after the 11th day. This evidence of the 
spontaneous reversal of rejection was consistent with the histopathol-
ogy of the autopsy liver at 21 days. (From Starzl T, Kaupp HA, Brock DR, 
Linman JW. Studies on the rejection of the transplanted homologous 
dog liver. (Surg Gynecol Obstet 1961;112:135-144, with permission.) 
J Am Coil Surg 
review 14 entitled "Brief Communication," published in 
1956 in the same Transplantation Bulletin as Welch's 
report of the year before. 
Cannon's description did not specify the species stud-
ied (presumably dog), and did not contain any specific 
information. Cannon acknowledged Welch's report as 
his inspiration, and alluded to <c ••• several successful op-
erations ... (liver replacements) without survival of the 
'patient' ... . " In a prophetic comment, he suggested 
that ... "the liver undoubtedly has a great deal to do with 
the production of the homograft reaction and probably 
with the inception and maintenance of tissue specificity. 
Replacement transplantation of intact liver, therefore, 
might well lead to interesting results." 
In early 1959, I learned that a team headed by the late 
Francis D Moore (Fig. 8) had begun the development of 
canine liver transplantation at the Peter Bent Brigham 
Hospital in June or July 1958, at the same time as my 
own first successful experiments. By the end of the sum-
mer of 1958, the Boston team had done six liver replace-
ments. These were reported in a 1959 issue of Trans-
plantation Bulletin. 15 I first met Moore at the 1960 
meeting of the American Surgical Association, where I 
discussed his presentation. 16 By then, the cumulative to-
tal of canine liver replacements in the 2 laboratories had 
increased to 111-31 in Boston and 80 in Chicago. The 
results were published separately in 1960 in different 
journals. 11.1 6 
Prerequisites for canine liver replacement 
The rwo prerequisites for perioperative survival of ca-
nine recipients were identified in both the Boston and 
Chicago laboratories. The first requirement was preven-
tion of ischemic injury to the allograft. This was accom-
plished in Boston by immersing the liver in iced saline, a 
method independently used for preservation of intesti-
nal and cardiac allografts by Lillehei and colleagues1? and 
by Lower and Shumway,l B respectively. 
Our exploitation of hypothermia in Chicago reflected 
the influence of F John Lewis, professor of surgery at 
Northwestern, who, with his Fellow, Norman Shumway, 
had pioneered total body hypothermia for open heart 
surgery at the University of Minnesota (Fig. 9). The 
livers were cooled by intravascular infusion of chilled 
solutions (Fig. 10), using thermal probes to monitor 
core temperatures (Fig. 11). Interestingly, this now uni-
versal practice had never been done before, apparently 
because oHear of damaging the microcirculation. Better 
Vol. 195. No.5. November 2002 
liver preservation was later obtained with infusates of 
differing osmotic, oncotic, and electrolyte composition: 
eg, the CoiJins,1 9 Schalm,20 and University of Wisconsin 
(UW) solutions21 '13 that originally were developed for 
kidney transplantation. 2 i ,2'; 
The second prerequisite for successful canine liver 
transplantation was avoidance of damage to the recipi-
ent splanchnic and systemic venous beds, the drainage of 
which was obstructed during host hepatectomy and 
graft implantation. This was accomplished in both the 
Boston and Chicago laboratories with decompressing 
external venovenous bypasses (Fig. 12). 
The pathology of liver rejection 
Until 1%0, the kidney had been the only organ allograft 
whose unmodified rejection had been systematically 
studied. Most transplanted canine livers were destroyed 
in 5 to 10 days. The survival of our dogs that lived for at 
least 4 days is shown in Fig, 13. The histopathologic 
studies were done in Chicago by Donald Brock2G (now 
retired in Northville, MI) and in Boston by the late 
Gustav Dammin27 (Fig. 14), Typically, a heavy concen-
tration of mononuclear cells was seen in the portal tri-
ads, and within and around the central veins. Hepato-
. . 
eyre necrosIs was extensive, 
A curious observation was made, however, in our 63 rd 
liver replacement experiment. 26 The recipient's serum 
bilirubin reached a peak at 11 days and then progres-
sively declined (Fig. 15, dashed line). The predominant 
histopathologic findings in the allograft by the 21 S( day 
were more those of repair and regeneration than of re-
jection. This was, to my knowledge, the first recorded 
exception to the existing dogma (based on skin graft 
research) that rejection, once begun, was inexorable. 
Five years later, the London pathologist, KA Porter (Fig. 
16), described similar findings in allografts of the first 
long-surviving canine liver recipients whose rejections 
had been reversed under immunosuppression in Den-
ver.2S In 1969, he extended his observations to human 
liver allografts. 29 
Because Porter's previous principal research had been 
kidney transplantation,30 he was now able to sort out 
features of rejection that were common to both organs 
(and various other allografts) in unmodified and immu-
nosuppressed recipients, and to distinguish these 
changes from those that were specific to the different 
kinds of organ allografts. Under the leadership of AJ 
Demetris at the University of Pittsburgh (Fig. 16), the 
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Figure 16. (A) KA Porter (1925-). In 1963. Porter. then a reader 
(and subsequently chairman) of pathology at SI. Mary's Hospital 
and Medical School, began a 35.year transatlantic collaboration 
with me. Porter's interests, which previously had been focused on 
the kidney,30 shifted to the liver in the mid 1960s.29 (B) Anthony J 
Demetris (1956-), founding chief of the Division of Transplantation 
Pathology at the University of Pittsburgh. After Porter's retirement, 
Demetris emerged as the doyen in the new field of transplantation 
pathology. 
field of clinical transplantation pathology rose from the 
base laid by the earlier workers. 
Variant liver transplant procedures 
The studies completed in Boston and Chicago defined , 
almost to the last detail, the liver replacement operation 
soon to be performed in humans. (Fig. 17). By the end of 
1959, we also had developed the operation of multivis-
ceral transplantation. Here, the allograft consisted of the 
liver and all of the other intraperitoneal organs (Fig. 
18)31.32. Essentially all of this work, and the development 
ofliver transplantation, was done with the help of Harry 
A Kaupp Jr, a skillful general surgery resident, who prac-
ticed vascular surgery in Allentown, PA, until his retire-
ment. Two medical students (Robert Lazarus and Rob-
ert Johnson) rounded out the team. 
Two further observations about rejection were made 
in the multivisceral experiments that were validated 
much later in rodent studies33.34 and in humans. 35 First, 
rejection of the different organs transplanted with the 
liver was less than rejection of the individual organs 
transplanted alone. Second, there was histopathologic 
evidence of a widespread graft versus host reaction in 
recipient tissues without resulting in overt graft versus 
host disease. 
Multivisceral transplantation and its modifications 
(Fig. 19) were applied in humans 30 years later6-39 and 
are now part of the conventional armamentarium of 
advanced organ transplant centers. When the operation 
594 Starzl Saga of Liver Replacement 
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Figure 17. Completed liver replacement in the dog. The fact that 
the recipient was a dog rather than a human is identifiable only by 
the multi lobar appearance of the liver. a., artery. (From: Brettschnei-
der L, Daloze P, Porter K, et al. The Use of combined preservation 
techniques for extended storage of orthatopic liver homografts . Surg 
Gynecol Obstet 1968;26:263-274; with permission). 
was first presented at the Surgical Forum of the Ameri-
can College of Surgeons in OctOber 1960,3l it was lam-
pooned. In fact, all surgical research in transplantation 
of the 1958 to 1960 era was considered na·ive or wasteful 
by many critics and especially by basic immunologists, 
most of whom viewed the immune barrier as 
impenetrable. 
Figure 19. The original canine multivisceral allograft (bottom cen-
ter) and its variations (arrows). All are used clinically today. 
J Am Coli Surg 
Figure 18. Canine multivisceral transplantation. The organs of the 
composite allograft are not shaded. (From: Surg Forum 11:28-30, 
1960; with permission). 
Immunosuppression by host cytoablation 
Just as this kind of surgical research in unmodified ani-
mals was losing momentum, it was dramatically revital-
ized by six successful human kidney transplantations 
performed between January 1959 and February 1962, 
first by Joseph Murray in BostOn,"O and then by the 
teams of Jean Hamburger4l and Rene KUSS42 in Paris 
(Fig. 20). Although "success" was defined as survival for 
at least 1 year, the first two recipients (both of fraternal 
twin kidneys) had continuous graft function for more 
than twO decades without post-transplant immunosup-
pression. All six patients had been conditioned before 
transplantation with sublethal doses of 450R tOtal body 
irradiation (Table 1, above dashed line). 
In an extension of the host preconditioning concept, 
the urologist, Willard Goodwin (Fig. 21), performed six 
human kidney transplantations at UCLA in 1960-1961 
in which host cytOablation was done with myelotoxic 
doses of cytOxan and methotrexate instead of tOtal body 
irradiation:3 Although five of the six recipients came to 
an early death, Goodwin successfully reversed several 
rejections with prednisone during the 143-day survival 
Vol. 195, No.5, November 2002 Starzl Saga of Liver Replacement 595 
Figure 20. Pioneers in kidney transplantation. Left to right: Joseph E Murray (1919-), Boston surgeon and 1990 Nobel Laureate; Jean 
Hamburger (1909-1992). Paris nephrologist; and Rene Kuss (1913-). Paris urologist. 
of his third patient, whose kidney was donated by her 
mother in September 1960. This crucial observation was 
not reported until 1963 and was not known to us until 
then. 
In any event, it quickly became apparent that the 
Boston and French successes with cyroablation for kid-
ney transplantation, remarkable though they were, 
would not be a bridge to liver transplantation. In our 
hands, total body irradiation precluded even periopera-
tive, much less extended, survival of canine liver 
recipients.';4 
Drug immunosuppression for clinical 
kidney transplantation 
A sea change occurred with the arrival of the drug 
6-mercaptopurine (6-MP). The key observation was 
Table 1.. Kidney Transplantation : Survival of 6 Months or 
More as of March 1963 (Above Dotted Line) 
Patient No. City (Ref) Date Donor Survival (mo) 
I Bosron (40) 1-24-59 Fraternal twin > 50 
2 Paris (41) 6-29-59 Fraternal twin >45 
3 Paris (42) 6-22-60 Unrelated- 18 (died) 
4 Paris (4 I) 12-19-60 Mother" > 12 (died) 
5 Paris (42) 3-12-61 Unrelated' 18 (died) 
6 PaJis (41) 2-12-62 Cousin' > 13 
7 Boston (54) 4-5-62 Unrelated 11 
Boston: JE Murray (patientS I and 7). 
Paris: J Hamburger (patientS 2, 4 and 6), R Kuss (patienrs 3 and 5). 
• Adjunc( st<:roid rherapy. 
that immune depression under 6-MP did not depend on 
overt bone marrow depression.45 The potential value of 
the drug in transplantation was first demonstrated in a 
rabbit skin graft model by Schwartz and Dameshek46 at 
Tuft's Medical School in Boston, and by the research 
team of Robert Good at the University of Minnesota:7 
Figure 21. Willard Goodwin (1915-1999), Founding Chief, Division 
of Urology, University of California Los Angeles (UCLA) and pioneer· 
ing kidney transplant surgeon . 
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Figure 22. Ph otograph in the 1980s of Roy Caine (1930-) and currently of Charles Zukoski 
(1926-). Both men tested 6-MP in the canine kidney transplant model in 1960 and reported 
encouraging results in the same year. 4SA9 
Prolongation of survival of canine kidney allografts un-
der 6-MP was reponed soon after by Roy Calne (in 
London)48 and Charles Zukoski (in Richmond)49 (Fig. 
22). 
By the end of 1960, CaIne (by now in Boston with 
Murray)50.51 and Zukoski (with David Hume in Rich-
mond)52 obtained survival of canine kidney recipienrs 
for 100 days or more under rreatmenr with 6-MP. Even 
be((er resulrs soon were reponed by Calne50 with aza-
thioprine an imidazole derivative of 6-MP. When clini-
cal kidney transplanr rrials with the new drugs were be-
gun in Bosron in 1960 and 1961, the possibility of 
rransplanring the human liver seemed close at hand. 
Before William R Waddell (Fig. 23) left the Massa-
chusem General Hospital ro become chair of surgery at 
the Universiry of Colorado in Denver on July 1, 1961, 
where I joined him from Nonhwestern a few monrhs 
Figure 23. William R Waddell (1919-) . Chairman. Department of 
Surgery. University of Colorado. 1961-1972. during the early days 
of clinical liver transplantation . He is retired in Silver City. NM. 
later, we setrled on clinical liver rransplanration as our 
highest prioriry. The plan was shelved in early 1962 
when we learned of disappoinring results in the clinical 
rrials of kidney transplation in Bos(On53 .54 and En-
gland.54 ray of hope could be found, however, in a repon 
by the future Nobel laureate, Murray, in the September, 
1962, issue of the Annals of Surgery. 53 
The anicle conrained a description of a kidney that 
had functioned under azathioprine therapy for 120 days, 
from the time of its rransplanration from an unrelated 
donor on April 5, 1962. That kidney still functioned at 
11 monrhs, 54 and was destined (0 suppon dialysis-free 
life of the recipienr for 17 monrhs. Although this was the 
only patienr who lived for as long as 6 monrhs, he be-
came the 7th human (0 survive more than 1 year after 
kidney transpJanration, and the first (0 do so without 
(Otal body irradiation (Table 1, below the dashed line). 
Figure 24. Thomas L Marchioro (1928-1995). Assistant and As-
sociate Professor of Surgery. University of Colorado from 1962 to 
1967. 
Vol. 195, NO.5, November 2002 
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Figure 25, Empirically developed immunosuppression used for kid-
ney transplant recipients in 1962-1963. Note the reversal of rejec-
tion with the addition of prednisone to azathioprine. More than a 
third of a century later, it was realized that the timing of drug 
administration had been in accord with the tolerogenic principles of 
immunosuppression described under "Mechanisms of Engraftment 
Tolerance: History Revisited ." 
In the meantime, we had obtained our own supply of 
azathioprine in the spring of 1962, and systematically eval-
uated it with the simpler canine kidney model rather than 
with liver transplantation. Many of the experiments were 
done with Tom Marchioro (Fig. 24), subsequently a re-
vered professor of surgery at the University of Washing-
ton (1967-1995). A5 in other laboratories, our yield of 
100-day canine lcidney transplant survivors was small. 
But two crucial findings were clinically relevant. First, 
canine kidney rejection developing under azathioprine 
invariably could be reversed with the addition of large 
doses of prednisone. 56 The second key observation was 
that a mean survival of 36 days in dogs treated with 
azathioprine was almost doubled when the animals also 
were pretreated with the drug for 7 ro 30 days57 (Table 
2). We committed to clinical trials of kidney and liver 
transplantation, in that order. Daily doses of azathio-
prine were to be given for 1 to 2 weeks before and after 
transplantation, with the addition of prednisone only to 
(feat rejection (Fig. 25). The renal program was opened 
in the autumn of 1962. 
The two features of the adaptive immune response to 
allografts that eventually would make transplantation of 
all kinds of organs feasible were promptly recognized. 
These were described in the title of the report of the first 
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Figure 26. Nine (19%) of the 46 live donor kidney recipients treated 
at the University of Colorado over an 18-month period beginning in 
the autumn of 1962. The solid portion of the horizontal bars depicts 
the time off immunosuppression. Note that the current serum cre-
atinine concentration (CR) is normal in all but one patient. *Mur-
dered: kidney allograft normal at autopsy. 
10 Colorado kidney cases: the reversibility of rejection, 
and more importantly, the subsequent development of 
donor specific tolerance.58 "Tolerance," which referred 
to the time-related decline of need for maintenance im-
munosuppression, proved to be the correct word. 
Nine of the 46 recipients of kidney allografts from 
live-related donors (20%) remained dialysis-free for 4 
decades, all but one with normal renal function through-
out. Seven of the nine became immunosuppression-free 
for periods ranging from 2112 to 38 years (Fig. 26). One 
of the nine was recently murdered in a love triangle and 
had a normal transplanted kidney at coroner's autopsy. 
Those remaining bear eight of the nine longest surviving 
Table 2. Influence of Pretreatment with Azathioprine on 
Post-transplant Longevity in Dogs 
Mean survival, 
n d SO SE 
Controls 21 10.8 2.75 .06 
Acure azarhioprine 21 36 13.7 3.0 
Azathioprine prerreatmenr 18 69.1 68.1 16.1 
Comparison of groups 2 and 3 (p < 0.001) . 
The rarionale for me practice of prerrearmenr wirh azamioprine is based on 
me 60-dog e.xperimenrs in which homorranspianrarion and bilareral ncphrec-
(Omy were performed. Unrreared animals lived for 10.8 :':: 0 .06 (SE) days. 
Animals mar received rrearmenr \Vim azarhioprine, mlHed on rhe day of 
operarion, lived 36 :':: 3.0 (S E) days. Animals rhar received preoperarive 
rrearmmr wirh azarhioprine for 7 ro 30 days, and posroperarive mcrapy, li ved 
for 69 :':: 16. 1 (SE) days. The difference between rhe twO groups was highly 
significanr (p < 0.001). (From Experience In Renal Transpianrarion. Phila-
delphia, PA: WE Saunders Company; 1964.) 
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Figure 27, Immunosuppression with azathioprine (Imuran.) and 
prednisone in first patient to survive orthotopic liver transplantation 
(patient 2). ACTl-C: doses of actinomycin C. (From: Strarzl TE, Mar-
chioro TL, Von Kaulla KN, et al. Homotransplantation of the liver in 
humans. Surg Gynecol Obstet 1963;117:659-676, with permis-
sion.) 
kidney allografts in the world tOday, including the four 
longest.59 
Human liver replacement: 1963 
Although the maximum foUowup of our first human 
renal recipient was only 6 months in the spring of 1963, 
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Figure 28. Rise in serum bilirubin to 12.8 mg% in the patient shown 
in Figure 27, 9 days after transplantation. The bilirubin declined after 
institution of high-dose prednisone therapy. (From: Strarzl TE, Marchi-
oro TL, Von Kaulla KN, et al. Homotransplantation of the liver in 
humans. Surg Gynecol Obstet 1963;117:659-676, with permission.) 
our kidney experience triggered the decision to go for-
ward with the infinitely more difficult trial ofliver trans-
plantation. The first attempt on March 1, 1963 was in 
B 
Figure 29, Original photomicrograph and verbatim caption published in 1963. "Specimens in Patient 2-A. left: Patient's own liver, 
showing hepatoma. B. right: Liver homograft obtained at autopsy 22 days after operation. Note good preservation of architecture. 
There was slight periportal fibrosis, which is thought to have antedated transplantation. Note mild cholestasis and fatty metamor-
phosis. A few aggregates of mononuclear cells were present in the periportal areas. Hematoxylin and eosin , x 19." (From: Strarzl TE, 
Marchioro TL, Von Kaulla KN, et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659-676, with 
permisSion.) 
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Figure 30. Extracorporeal perfusion of the cadaver donors reported 
in 1963. "The venous deainage was from the inferior vena cava and 
the arterial inflow was through the aorta after insertion of the 
catheters through the femoral vessels. Note clamp on thoracic aorta 
to perfuse the lower half of the corpse selectively. A glucose primed 
pump oxygenator was used with a heat exchanger." (From: Starzl TE, 
Marchioro Tl, Von Kaulla KN, et al. Homotransplantation of the liver 
in humans. Surg Gynecol Obstet 1963;117:659-676, with permis-
sion.) 
an unconscious and ventilator-bound child with biliary 
atresia who bled to death during operation. The next 
twO recipients, both adults, died 22 and 7.5 days after 
their transplantations on May 5 and June 3, 1963 for the 
indication of primary liver malignancies (Table 3). The 
two adults were found at autopsy to have extrahepatic 
micrometastases. The three failed cases were described in 
the December 1963 issue of Surgery, Gynecology, and 
Table 3. The First Seven Human Liver Recipients 
Age Liver 
(y) Date City (ref) disease 
3 3-1-63 Denver (60) Biliaryanesia 
48 5-5-63 Denver (60) HepatOma, cirrhosis 
68 6-3-63 Denver (60) DuCt ceU carcinoma 
52 7-10-63 Denver (64) HepatOma, cirrhosis 
58 9-1 6-63 Bos[on (65) Colon metastases 
29 10-4-63 Denver (64) HepatOma 
75 1-?-64 Paris (66) Colon metaStases 
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Figure 31. liver injury tests after hepatic transplantation in patient 
2 of the 1963 report . "Note modest rise in serum glutamic-
oxaloacetic transaminase (SGOT) with subsequent decline. lactic 
dehydrogenase (lDH) and serum glutamic pyruvic acid transami-
nase (SGPT) were similarly affected." (From: Starzl TE, Marchioro Tl, 
Von Kaulla KN. et al. Homotransplantation of the liver in humans. 
Surg Gynecol Obstet 1963;117:659-676. with permission.) 
Obstetrics,60 2 months after the optimistic kidney report 
in the same journaJ.58 
Immunosuppression was the same as that used for our 
kidney recipients. Pretreatment was begun with azathio-
prine with or without small doses of prednisone. The 
same therapy was continued after transplantation. With 
evidence of rejection, a high-dose course of prednisone 
was added (Fig. 27). Rejections, which were monitored 
by serial serum bilirubin concen trations, were easily re-
versed (Fig. 28). The transplanted livers retrieved at au-
topsy were remarkably free of rejection, as noted in the 
Survival Main cause of 
(d) death 
0 Imraoperarive bleeding 
22 Pulmonary emboli, sepsis 
75 Pulmonary emboli 
6.5 Gasrroimesrinal bleeding, pulmonary 
emboli/edema, liver failure 
11 Pneumonitis, hepatic abscesses, failure 
23 Sepsis, bile peritOnitis, pulmonary emobli 
0 I mraoperative hemorrhage 
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Figure 32. Details of human liver replacement. (A) External by-
passes for decompression of the inferior vena caval and splanchnic 
venous beds . (8) Anastomosis of suprahepatic inferior vena cava. 
Note that the cuff of the homograft is actually a confluence of the 
hepatic veins and the vena cava. (C) Subhepatic operative field after 
completion of all anastomoses . Note that gallbladder has been 
removed and that the T tube is inserted through a stab wound in the 
recipient portion of the composite common duct. (From: Starzl TE. 
Marchioro TL. Von Kaulla KN. et al. Homotransplantation of the liver 
in humans. Surg Gynecol Obstet 1963;117:659-676. with permis-
sion.) 
caption describing the histopathology of the 22-day 
graft (Fig. 29, right). 
Efficiem aJlograft preservation was accomplished by 
transfemoral infusion of a chilled pelfusate imo the 
aorta of the nonheart- beating donors after cross-
clamping the aorta at the diaphragm61 (Fig. 30). The 
procedure was the same in principle as that of first stage 
of the "flexible" multiple organ procuremem operarion 
currently used worldwide. 62 There was very little isch-
emic damage to the allografts during their postmortem 
imervals of O~ to 8 hours, as indicated by modest in-
creases in the liver injury tests (Fig. 31). 
The various anastomoses were performed in the same 
way as in the canine experimems (Fig. 32). The lethal 
J Am Coli Surg 
Figure 33. Paul Terasaki. PhD (1929-). the basic scientist at UCLA 
who became a father of tissue matching. 
mistake in the human cases was the use of passive veno-
venous bypasses (Fig. 32). Emboli formed in the bypass 
tubing, migrated to the lungs, and caused or comributed 
to the deaths of all 1963 Denver recipients who survived 
the operation (Table 3). Overzealous correction of clot-
Figure 34. Canine recip ient of an orthotopic I iver homograft. 5 
years later. The operation was on March 23. 1964. The dog was 
treated for only 120 days with azathioprine and died of old age after 
13 years. 
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Figure 35. "An auxiliary homograft (right) and the recipient dog's 
own liver (left). Note the well·preserved but diminutive structure of 
the liver homograft. The gallbladder did not shrink proportionately . 
The specimens were obtained 45 days after transplantation." 
(From: Ann Surg 1964;160:411-439, with permission .) 
ting abnormalities may have contributed to the compli-
cation. In much the same way as roday, coagulation had 
been monirored with serial thromboelastograms and 
corrected with blood components and with epsilon 
amino caproic acid (an analogue of the currenrly used 
aprotinine). 
The supreme irony was that the venous decompres-
sion that had been critical in the dog experiments is not 
mandarory in most human liver recipients. The moror-
driven venovenous bypass system, which was introduced 
in Pirrsburgh in the 1980s,63 made the procedure easier. 
In some centers, however, it now is used only selectively. 
The aftermath 
During the last half of 1963, rwo more attempts at liver 
transplantation were made in Denver,64 and one each in 
Boston65 and Paris,66 (Table 3). Clinical activiry then 
ceased for 3\12 years. The worldwide morarorium was 
voluntary. The decision ro stop was reinforced, though, 
by widespread criticism of attempting to replace an un-
paired vital organ with an operation that had come to be 
perceived as too difficult to ever be tried again. 
In contrast, kidney transplantation thrived at the 
Universiry of Colorado. In 1964, a textbook was pro-
duced based on our first 70 cases, emphasizing that renal 
transplantation had reached the level of a bona fide clin-
ical service. 67 At the beginning of 1963, the only three 
clinically active kidney transplant programs in the 
United States were at the long-standing Brigham center 
and the rwo opened in 1962: ours and David Hume's in 
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Figure 36. Carl Groth (1933-), current president of the Interna· 
tional Transplantation Society. After two stints at the University of 
Colorado (1966-1968 and 1971-1972), Groth returned to Stock· 
holm as the founding chairman of the first Department of Transplan· 
tation in the world located at the Huddinge Hospital of the Karolin· 
ska Institute, Stockholm. He retired in 2000. 
Richmond, VA. One year later, nearly 50 kidney teams 
had started or were gearing up. A similar proliferation 
was going on throughout Europe. 
The liver moratorium 
Advances were made berween January 1964, and the 
summer of 1967, most of which were applicable to all 
organs. 
Role of HLA matching 
In a clinical collaboration with Paul Terasaki of UCLA 
(Fig. 33), it was shown tharrhe qualiry ofHLA matching 
short of perfect compatibiliry had Iitrle association with 
kidney transplant ourcome.6S.70 By inference, desper-
ately ill liver, heart, and other transplant candidates who 
could not wait for a well-matched organ would not suf-
fer a significant penalry by receiving a mismatched one. 
Development of antilymphocyte globulin 
A second objective was to improve immunosuppression. 
Antilymphocyte globulin (ALG) was prepared from an-
tilymphocyte serum (ALS) obtained from horses immu-
nized against dog and human lymphoid cells.7J Mter its 
development and testing in dogs berween 1963 and 
1966, human-specific ALG was introduced clinically in 
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Figure 37. The first three human recipients to have prolonged 
sUNival after liver replacements in July and August, 1967 . The adult, 
Carl Groth, was then an NIH-supported Fellow. 
1966 in combination with azathioprine and prednisone 
(the "triple drug cocktail") . 
In the preclinical canine studies, the efficacy of dog-
specific ALG had been demonstrated when it was given 
before, at the time of, or after kidney and liver transplan-
tation. It was noted that " ... pretreatment [with ALG) 
did appear to be of value in the canine experiments , and 
was accordingly made part of the protocol used for pa-
) Am Coli Surg 
Figure 38. Rolf Zinkernagel (1944-) . Swiss physician-immunologist 
whose discovery (with Peter Doherty) of the mechanisms of the 
adaptive immune response to noncytopathic microorganisms 
earned the Nobel prize in 1996. 
tients."71 The conclusion about the efficacy of pretreat-
ment was consistent with previous rodent studies of ALS 
by Woodruff and Anderson72 and by Monaco, Wood, 
Gray, and Russell. 73 
Demonstration of hepatic tolerogenicity 
The goal in Denver of resuming clinical liver transplan-
tation was reflected by a growing kennel population of 
long surviving canine recipients (Fig. 34), none of whom 
were treated with more than a 4-month course of aza-
thioprine/8 or a few doses of ALG.7 1 In presenting the 
results of 143 canine liver replacements to the Society of 
University Surgeons in February 1965, I emphasized that 
... Although the early recovery after liver homo-
rransplanrations has many hazards ... the frequency 
Table 4. First Successful Transplantation of Human Allografts (Survival > 6 Months) 
Organ City Date Physician/surgeon Reference 
Kidney Bosmn 1/24/59 Merrill/Mlliray 40 
Liver Denver 7/23167 Smrzl 84 
Hearr Capemwn ]/2/68 Barnard/Shumway 86,87 
Lung' Ghent 1111 4/68 Derom 88 
Pancreast Minneapolis 6/3/69 Lillehei 89 
'Patient died after 10 month s; all orhers in tab le lived more than I year with funcrioninggrafr. The first survival longer rhan I year ofisolarcd lung recipients was 
nOt reponed until 1987. 
tKidney and pancreas al lografts in uremic patient. 
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and rapidity with which dogs could be withdrawn 
from immunosuppression without an ensuing fatal 
rejection is remarkable .... The consistency of this 
state of host-graft nonreactivity and the rapidity with 
which it seemed to develop exceeds that reported 
after canine renal homo transplantations. 28 
A year later, the French surgeon, Henri Garnier, reported 
(with Cordier) that a significant percentage of untreated 
outbred pig liver recipients did not reject their allografts?4 
This observation promptly was confirmed and extended in 
England by Calne at Cambridge,75 Peacock and Terblanche 
in Bristol,76 and us.77 Calne and coworkers7S subsequently 
demonstrated that the tolerance self-induced by the liver 
extended to other tissues and organs from the liver donor, 
but not from third-party pigs. 
Reassessment of the auxiliary liver graft 
Although our primary focus during the moratorium was 
on liver replacement, we also evaluated the ostensibly 
less radical auxiliary liver transplantation (Welch's oper-
ation). Mter showing that rejection could be completely 
prevented in some dogs with high doses of azathioprine, 
it was proved that the acute atrophy of Welch's auxiliary 
livers was caused by depriving the allografts of liver sup-
porting constituents of splanchnic venous blood.64,79 At 
the time of transplantation 45 days previously, the di-
minutive rejection-free allograft shown in Fig. 35 had 
been the same size as the recipient's normally vascular-
ized liver. 
These findings, which finalized the decision to pro-
ceed clinically with liver replacement, were not fully 
explained until the mid-1970s. Eventually, it was es-
tablished that endogenous insulin was the most im-
portant "hepatotrophic" factor in normal portal 
blood.80.81 This was a decisive step in understanding 
the pathophysiology of Eck's fistula (portacaval 
shunt).81,82 
Improved organ preservation 
The potential pitfall of organ preservation remained. It 
would still be necessary to obtain livers from nonheart-
beating donors. To help surmount this difficulty, we 
developed an ex vivo perfusion system in 1966 and 1967 
that permitted reliable preservation of canine livers for as 
long as a day. The effort was spearheaded by a young 
naval surgeon, Larry Brettschneider.83 Now, it was time 
to try again. 
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Resumption of human liver replacement 
When the liver program reopened in July, 1967, it had 
another weapon. This was an enthusiastic 2-year NIH-
supported Fellow from Stockholm named Carl Groth 
(Fig. 36). Groth who was determined to succeed, and 
had no doubt that this would be possible, was a key 
member of both donor and recipient surgical teams. He 
also took charge of the post-transplant management 
team in a continuous vigil that lasted for many months. 
By the end of the year, multiple examples of prolonged 
human liver recipient survival had been produced, un-
der triple drug immunosuppression: azathioprine, pred-
nisone, and ALG84 (Fig. 37). The liver transplant beach-
head was reinforced by the opening of Roy Calne's 
clinical program in Cambridge, England, in February 
1968.8 In 1969, a companion to the 1964 kidney trans-
plant book was published, entitled Experience in Hepatic 
Transplantation,85 based on our first 25 liver replace-
ments and 8 performed elsewhere (4 by Caine). 
Transplantation of other extrarenal organs followed 
close behind the liver, using similar immunosuppression 
(Table 4). Hearts were successfully transplanted in 1968 
in Capetown by Barnard86 and in Palo Alto by Shum-
way.87 In 1969, the first prolonged survival after human 
lung88 and pancreas transplantation89 was accomplished 
in Ghent and Minneapolis, respectively. But transplan-
tation of the extrarenal organs, and especially of the liver, 
remained controversial for another decade, because of 
the high mortality. Swimming against the stream, the 
German and French teams of Rudolf Pichlmayr and 
Henri Bismuth entered the field in the early 1970s, as 
did the Dutch group of Rudi Krom later in the decade. 
The unusual tolerogenicity of the hepatic allograft 
previously demonstrated in dogs and pigs was evident in 
human liver recipients of the 1970s. In 1995, 12 of our 
42 patients (28%) surviving from this era already had 
been off all immunosuppression for 1 to 17 years. 90 
Since then, many of the remaining 30, who are now out 
to 33 years post-transplantation, also have stopped drugs 
and remain welJ.91,92 Such drug-free tolerance was almost 
unheard of with the other kinds of cadaveric organs. 
Advent of better drugs 
Despite such encouraging notations, the widespread use 
of the liver and other extrarenal organs was precluded for 
another decade by the high mortality. The outlook for all 
organs improved after cyclosporine was introduced clin-
ically in England in 1978 by Calne,93 and combined 
604 Starzl Saga of Liver Replacement 
with prednisone in Denver 1 year later.94 Results further 
improved when tacrolimus was substituted for cyclo-
sporine in the 1990s.95 
The increases in liver recipient survival with the two 
new drugs were particularly striking,96,97 but less dra-
matic gains were recorded with the other organs. By the 
end of the 20th century, transplantation of the liver and 
all of the other vital organs had become an integral part 
of sophisticated medical practice in every developed 
country in the world. There was, however, one nagging 
disappointment. 
With better immunosuppressants, drug-free liver re-
cipients were expected to become common. Yet, the ul-
timate prize of tolerance was achieved less frequently 
than before, and only when liver transplantation was 
carried out during three time periods. The first two in-
tervals were 1979-1980 and 1989-1990, just after cyclo-
sporine 96 and tacrolimus,95,97 respectively, were intro-
duced clinically as monotherapy, adding prednisone 
only to treat rejection, 
When prophylactic high doses of prednisone and 
other agents were added at the time of operation in an 
effort to further reduce the threat of acute rejection, 
drug-free tolerance was no longer seen. The third cluster 
of tolerant patients was produced at the turn of the cen-
tury in Kyoto, Japan, where many pediatric recipients of 
partial livers from parental donors were successfully 
weaned from a steroid-sparing tacrolimus-based regi-
men of immunosuppression98 similar to that originally 
used in 1989-1990.97 
Mechanisms of engraftment-tolerance: 
History revisited 
Despite these "proof of feasibility" observations, the 
goal of deliberate induction of drug-free tolerance 
would remain out of reach until the mechanisms lead-
ing to this state were understood. Insight into the 
mechanisms began to emerge in 1992 with the study 
up to 30 years post-transplantation of 5 kidney and 
25 liver recipients. 
The kidney recipients were survivors from the 1962-
1967 era that has been the main focus of this review; 
most of the liver recipients had undergone transplanta-
tion in the 1970s. Samples were obtained of the allo-
grafts and of host blood, skin, lymph nodes, and, in 
some cases, other organs such as bowel and heart. In all 
30 patients, including several who had long since 
stopped all immunosuppression, small numbers of do-
J Am Coli Surg 
nor hematolymphopoietic cells were demonstrated in 
blood or tissues,99,loo a condition known as donor leuko-
cyte chimerism. 
These findings prompted numerous studies in animal 
models,101-109 and ultimately led to a collaboration with 
RolfZinkernagei of Zurich (Fig. 38) whose 1996 Nobel 
prize was for studies of the adaptive immunity responsi-
ble for defense against noncytopathic microorganism 
and for rej ection. 1 10 At the end, the chimerism-
associated mechanisms of organ and bone marrow cell 
engraftment, and of acquired tolerance, were delineat-
ed. lll ,112 Only then was it possible to fully explain the 
meaning of the historical events that I have been describ-
ing. More importantly, a map for the future of organ 
transplantation could be drawn. 
In essence, organ engraftment is a dynamic process 
initiated and governed by the migration and localization 
of the passenger leukocytes of bone marrow origin (ie, 
hematolymphopoietic cells) that are normal constitu-
ents of all tissues and organs. The donor leukocytes mi-
grate preferentially to the host lymphoid organsl04,113-II5 
(Fig. 39, left), where they induce an antigraft T-cell re-
sponse. Without immunosuppression, this response 
proceeds to rejection in humans and in most animal 
models. 
In a few experimental models of spontaneous toler-
ance, however, or under the appropriate conditions of 
immunosuppression, the immune response is too weak 
to eliminate the migratory donor leukocytes and re-
gresses. Collapse of the response occurs when the acti-
vated host T-cell clone reaches a proliferation limit and is 
exhausted and deleted by incompletely understood 
mechanisms that include apoptosis109 (Fig. 40). Clonal 
exhaustion-deletion is the seminal mechanism of organ 
engraftment and of acquired tolerance.99,100,l1l,112,II6 Be-
cause the exhaustion is never complete, maintenance of 
the variable deletional tolerance achieved at the outset 
depends on the persistence of residual stimulatory donor 
leukocytes. I I I,ll L These were the cells discovered up to 30 
years after transplantation in our pioneer organ 
recipients. 
The important point is that allograft rejection and 
clonal exhaustion-deletion are products of the same 
donor-specific immune response. The close relation 
of rejection and deletional tolerance is exemplified by 
the results with pig liver transplantation in the mid-
1960s (see earlier) .74-78 The immune response re-
ported in the majority of untreated pig liver recipients 
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proceeds to rejection (Fig. 41A, ascending thick ar-
row). In a significant minority of experiments, how-
ever, the response is exhausted and deleted (Fig. 41A, 
decline of the thin-line curve). Unlike the liver, pig 
kidneys and other porcine organs fail to induce toler-
ance because they are endowed with a smaller quan-
tity of passenger leukocytes. 
In contrast to its unpredictable occurrence in un-
treated pigs, spontaneous tolerance invariably is induced 
by hepatic allografts in numerous inbred rodent mod-
elS. 103.117,118 This is not, however, an exclusive quality of 
the liver. Spontaneous tolerance also can be induced in 
experimental rodent models by less well leukocyte-
endowed heart119.12o and kidney allografts,121.123 albeit 
less commonly. 
In experimental models in which organ allograft re-
jection by the unmodified recipient is the normal out-
come, the passenger leukocyte-induced response can be 
reduced enough to be deleted by treating the recipient 
prior to transplantation (Fig. 41B). That almost cer-
tainly is what Murray and colleagues40 and Hamburger 
and associates41 accomplished with pretransplant total 
body irradiation of their historic fraternal twin kidney 
recipients of 1959. Less drastic pretreatment is possible 
with thoracic duct drainage,124,125 total lymphoid irradi-
ation,126 conventional antirejection drugs,57,125 and espe-
. 11 h '1 h'd 'b d . 71-73.127128 Cla y t e ann ymp 01 antI 0 y preparatIons. ' 
Prototypes of effective antilymphoid preparations that 
have been used for pretreatment include the polyclonal 
ALGs of the kind developed and introduced clinically 
during the liver transplant moratorium of 1964-1967,7" 
and the humanized monoclonal ALG, alemtuzumab 
that has been extensively evaluated clinically by Caine 
and colleagues. 129,130 
The antigraft response also can be brought into the 
deletable range by immunosuppression given after 
transplantation (Fig. 41 C); This, though, is a double-
edged sword. If antigen-specific immune activation is 
unduly depressed (Fig. 41D), the derivative event of 
exhaustion-deletion also is eroded. When immuno-
suppression is reduced later in an initially over-treated 
recipient, the unde1eted donor-specific clone recovers 
along with the return of global immune reactivi-
ty.10G.112 Graft survival is then dependent on perma-
nent immunosuppression. 
Two principles of tolerogenic immunosuppression 
derive from this paradigm.112 The first is the value of 
recipient pretreatment. The second is the importance of 
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Figure 39. Initial preferential migration of passenger leukocytes 
from organ allografts to host lymphoid organs (left). After about 30 
days, many of the surviving cells move on to non lymphoid sites 
(right). 
limiting post-transplant immunosuppression to the 
minimum needed to prevent irreversible immune dam-
age to the transplanted organ. In this view, the primary 
role of immunosuppression is not to eliminate the anti-
graft response as has been commonly assumed, but 
rather to lower it into the deletable range . 
Both therapeutic principles had been observed empir-
ically in the early Denver renal transplant experience 
that resulted in a unique cohort of drug-free kidney re-
cipients and prompted the first liver trial. Pretreatment 
of these patients as well as minimal post-transplant im-
munosuppression was given with azathioprine, adding 
prednisone temporarily only to treat rejection (Fig. 25). 
Figure 40. Clonal exhaustion-deletion, the seminal mechanism of 
organ engraftment, and of acquired tolerance. Persistence of some 
donor cells is a prerequisite for maintenance of the variable dele-
tional tolerance induced by the initial surge of donor cells. 
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Figure 41. Rather than producing rejection (thick arrows). the donor-specific immune response may be exhausted and deleted as depicted 
by the fall of the initially ascending continuous thin lines when: (A) The unmodified recipient response is too weak to eliminate the migratory 
donor cells (spontaneous tolerance). (8) Recipient immune responsiveness is weakened by cytoablation or cytoreduction in advance of 
transplantation. (C) The recipient response is reduced into the deletable range by immunosuppression (black bar) after transplantation. When 
excessive immunosuppression (multilayered bars) is given after arrival ofthe allograft. In contrast. panel D shows how over-treatment reduces 
the efficiency and extent of clonal exhaustion-deletion and is therefore anti-tolerogenic (see text). Horizontal axis: time. Tx: transplantation. 
No comparable series of tolerant kidney recipients was 
compiled anywhere in the world during the next 40 
years. What had changed? 
First, pretreatment of kidney recipients was deem-
phasized or abandoned in December 1963 after infec-
tious complications occurred in the preoperative pe-
riod (Fig. 42). Second, high doses of prednisone were 
instituted at the time of transplantation because of 
the excessive loss of kidney allografts to uncontrolla-
ble rejection (Fig. 42). Although heavy prophylactic 
immunosuppression has dominated transplantation 
practice ever since (Fig. 4ID), the superior tolero-
genic qualities of hepatic allografts continued to re-
sult in a handful of drug-free tolerant liver recipients, 
but only in isolated periods when restrictive post-
transplant immunosuppression was used. 
Back to the future 
With the insight into the mechanisms of engraftment 
that I have described, we have applied both therapeutic 
principles in more than 200 cases since July, 200 I. Kid-
ney, liver, pancreas, and intestinal recipients were pre-
treated with a single large dose of a potent ALG, and 
then administered conservative doses of tacrolimus after 
transplantation. No other immunosuppression was 
given unless specifically indicated for rejection (Fig. 43). 
Half of these patients have been weaned after 4 
months to only one, two, or three doses per week of 
tacrolimus. Many are expected to become drug free in 
their second post-transplant year. These results suggest 
that a. high, if not absolute, degree of sustained donor 
specific nonreactivity (ie, tolerance) can be expected af-
rer the transplantation of all organs. So, the next, and 
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Figure 42. Treatment revisions in immunosuppression made at the 
University of Colorado in December 1963. that unwittingly violated 
both principles of tolerogenic immunosuppression shown in Figure 
43. Pretreatment was deemphasized or eliminated. and high doses 
of prednisone were given prophylactically instead of as needed. 
Acute rejection was frequently prevented. but drug-free tolerance 
was no longer seen. 
perhaps the most gratifYing, phase of transplantation 
may already have begun. But, of course, that will be a 
story for future Congresses of the American College of 
Surgeons. 
Postscript 
That concludes my remarks except for a postscript. In 
the early 1960s, Sir Peter Medawar, Nobel laureate and 
founder of the discipline of transplantation immunol-
ogy, wrote the following: 
Good scientists study the most important problems 
they think they can solve. It is, after all, their profes-
sional business to solve problems, not merely to grap-
ple with them. The spectacle of a scientist locked in 
combat with the forces of ignorance is not an inspir-
ing one if, in the outcome, the scientist is routed. 131 
Medawar was referring to the search for the "holy 
grail" of transplantation, the secret that would allow 
organ recipients to be rendered drug-free tolerant. 
Thousands of scientists joined the crusade, driven by the 
false premise that successful engraftment after organ 
transplantation occurred by fundamentally different 
mechanisms than the donor leukocyte chimerism-
associated ones of bone marrow transplantation and of 
acquired tolerance. This assumption was not challenged 
for the next third of a century. 
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All the while, the historical observations that I have 
recounted pointed in a different direction, and in the 
end these observations were at least as important in ar-
riving at the truth as the results from reductionist inves-
tigations. The lesson is clear. History is neither dull nor 
dead. It is a uniquely human survival tool, aiding those 
in the present by the ability to draw on the past to meet 
current needs, and to predict needs yet to come. 
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